Adaptimmune(ADAP)
Search documents
Adaptimmune(ADAP) - 2019 Q3 - Quarterly Report
2019-11-06 16:55
Table of Contents ADAP The Nasdaq Global Select Market UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2019 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number 001-37368 ADAPTIMMUNE THERAPEUTICS PLC (Exact name of Registrant as specified in its charter) England and Wales Not Ap ...
Adaptimmune(ADAP) - 2019 Q2 - Earnings Call Transcript
2019-08-03 21:42
Adaptimmune Therapeutics plc (NASDAQ:ADAP) Q2 2019 Results Conference Call August 1, 2019 8:00 AM ET Company Participants Juli Miller - IR James Noble - CEO Adrian Rawcliffe - Incoming CEO Rafael Amado - President, R&D Conference Call Participants Waleed Abdel-Naby - SunTrust Robinson Humphrey Kelsey Goodwin - Guggenheim Securities Marc Frahm - Cowen Keith Tapper - Citi Jonathan Chang - SVB Leerink Jim Birchenough - Wells Fargo Tony Butler - Roth Capital Partners Operator Good morning, and welcome to the Se ...
Adaptimmune(ADAP) - 2019 Q2 - Quarterly Report
2019-08-01 15:59
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2019 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number 001-37368 ADAPTIMMUNE THERAPEUTICS PLC (Exact name of Registrant as specified in its charter) England and Wales Not Applicable (State or other jurisdiction of i ...
Adaptimmune(ADAP) - 2019 Q1 - Quarterly Report
2019-05-06 18:57
Table of Contents ADAP The Nasdaq Global Select Market UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2019 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number 001-37368 ADAPTIMMUNE THERAPEUTICS PLC (Exact name of Registrant as specified in its charter) England and Wales Not Applic ...
Adaptimmune(ADAP) - 2018 Q4 - Annual Report
2019-02-27 22:22
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2018 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number 001-37368 ADAPTIMMUNE THERAPEUTICS PLC (Exact name of Registrant as specified in its charter) England and Wales Not Applicable (State or other jurisdiction of incor ...